SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 ($QQQ) is experiencing high volatility as traders grapple with mixed signals and a sharp intraday reversal. Community discussions center around potential market manipulation, the impact of $NVDA's earnings, and speculation about future interest rate decisions. Some traders are anticipating a bounce, while others fear a deeper correction, creating uncertainty around the direction of the tech-heavy ETF.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull ($BULL) is trending as investors discuss its latest earnings report, with community members debating whether positive results will be enough to overcome negative market sentiment. Discussions also include speculation about potential upgrades, institutional interest, and comparisons to similar companies like SoFi. Some traders are closely watching for guidance from the earnings call and anticipate increased volatility.

SSgA Active Trust - SPDR S&P 500 ETF Trust

Amidst broad market volatility and tech sector struggles, the SPY is trending as the community debates whether this pullback signals a buying opportunity or the start of a deeper correction. Discussion revolves around potential catalysts, including the impact of economic data, Fed policy, and geopolitical events, while some traders point to technical indicators suggesting oversold conditions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending after a significant investment in Performance Drone Works (PDW), a U.S. defense technology company specializing in AI-enabled combat robotics, as well as an $8.2M contract win. The community is discussing the potential impact of this investment on production scaling and Ondas's position in the autonomous defense sector. Despite market volatility, many express optimism about ONDS's growth potential and ability to secure further contracts.

BlackRock Institutional Trust Company N.A. - iShares Russell 2000 ETF

iShares Russell 2000 ETF

IWM is trending due to concerns about the small-cap sector's vulnerability amid fading rate cut hopes and institutional put buying, with community members closely watching key support levels and potential downside risks. Discussions revolve around whether the ETF can reclaim crucial price levels, as some traders point to technical formations suggesting further declines while others anticipate a potential oversold bounce. Overall, the conversation highlights uncertainty and a cautious outlook for small-cap performance in the near term.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology (MU) is trending amidst a broader market downturn, with community chatter focused on a recent price drop from multi-year highs. Despite positive analyst ratings and long-term growth prospects tied to AI-driven memory demand, some traders believe MU was overbought, leading to profit-taking and increased volatility. Traders are closely watching for a potential bounce and upcoming earnings data.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending as investors digest recent earnings, a planned move to the Nasdaq, and a CEO transition. Community members are discussing whether Walmart is a safe haven amid market uncertainty, while also weighing the impact of consumer spending trends and SNAP benefits. Some traders are analyzing technical patterns, while others are highlighting Walmart's push into e-commerce and AI.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

BMNR is trending downwards, with community members expressing concerns about the stock's performance relative to ETH and overall crypto market conditions. Disappointment and frustration are directed towards figures like Tom Lee, with skepticism surrounding price predictions and strategic decisions. Investors are closely watching for potential earnings catalysts or staking strategy announcements that could shift momentum.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss its recent price decline and potential for a rebound ahead of upcoming earnings, with some citing market manipulation and overselling as key factors; the community is also weighing the impact of potential profitability and new partnerships on the stock's future performance amid broader concerns about the EV sector and the overall market.

Pump Mind Virus is a Pure Meme with a long term vision. We are building for the future while making no promises about the present. The project aims to bring the spirit of community memes back to the Solana ecosystem. We do that with engaging content and memes. Culture through community. Viral spread by word of mouth.  And most importantly, by not using the fake hype machine that has come to dominate the meme coin landscape.

PumpMindVirus

PumpMindVirus ($PMV) is trending due to its highly engaged community and meme-driven hype, with many users playfully discussing the "infection" spreading from $PUMP on $SOL. The community is focused on building momentum and attracting attention as it approaches a $1M market cap, with some suggesting it's a low-cap gem with significant potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said the probe identified issues in its financial reporting and that it had restated its previously issued financial statements.</li><li>PACS now expects core profit for the full year to be in the range of $480 million to $490 million, above an $472.72 million expected by analysts.&nbsp;</li><li>Revenue for the full year is expected to be in the range of $5.25 billion to $5.35 billion.</li></ul>Shares of PACS Group, Inc. (PACS) jumped 53% in the pre-market session on Thursday after the company said that an audit committee had completed its independent investigation into the allegations made by short seller Hindenburg Research in its report in November 2024.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pacs.com/news-events/press-releases/detail/121/pacs-group-inc-reports-third-quarter-2025-results">said </a>that the recommendations by the committee have been or are being implemented. The company said that the probe identified issues within its financial reporting and restated its previously issued financial statements, including a $46.1 million reduction in the revenue reported for the three-month period ended June 30, 2024.“...today is the start of a new chapter for PACS,” said CEO Jason Murray in a call with analysts on Wednesday while reiterating efforts to build trust with stakeholders.<h2 class="st-heading-2">Outlook For The Year Ahead</h2>The company now expects core profit for the full year to be in the range of $480 million to $490 million, above the $472.72 million expected by analysts, according to data from Fiscal AI.Revenue for the full year is expected to be in the range of $5.25 billion to $5.35 billion, up from an expected $4.6 billion.<h2 class="st-heading-2">Q3 Earnings</h2>The company reported third quarter revenue of $1.34 billion, an increase of 31.0% over prior year, and above an estimated $949.48 million.Core profit for the three months was $131.5 million, above an estimated $85.90 million.PACS Group is a holding company investing in post-acute healthcare facilities. Its units operate 320 care facilities across 17 states.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PACS stayed within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels. However, retail sentiment around PACS hit its highest levels this year on Thursday.<figure class="image"><img style="aspect-ratio:623/60;" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAm8AAAA8CAYAAAAws134AAAQAElEQVR4Aex9C1hU17n2u7k4gyAMGJAxenSiUVHbRHMzNImVnPhXKH8NmptU80SURlHbBJP/bx/Tp0+ObZ+2mp5c0FTEPPEcjKZe0nDEHq2kqVE0idocDRAvGYzoTEAZVGAGGOCsb88MzAxz5Tow3zx77b3XWt/61rfe2fPy7fXttQlp5w8jwAgwAowAI8AIMAKMwKBBIAT8YQQYAUaAEWAEuoUAN2IEGIGBQICdt4FAnftkBBgBRoARYAQYAUagmwiw89ZN4LhZYCHA1jACjAAjwAgwAsGCgEfnrbm5BXV1t1BdXYurV2s4MQZ8DfA1MCDXAHEQcRFxUm+TM+kk3dQH8xzzPF8DQXkNDAivOV9rxEHERcRJ3njOrfNGCgyGmwgLC0NsbDTU6tswenQ8J8aArwG+Bvr1GiDuIQ4iLiJOIm7yRmy+1pMu0km6qQ/qi3mOeZ6vAb4G+vsaIO4hDiIuIk4ibvLEYyGuKq9fvyEXJyTEISoqAuHhYZAkSS7jHSPACDAC/YmAJEkyBxEXESdR3zaOovPuJpsO0km6A4LnujsYbscIMAKDGgFJ8o/nujhv5O2FhoZApRrBDtugvhTYeEZg6CEgSZLMTcRRxFXdHSG1JR3Mc91FkNsxAoxAXyEgSd55zsF5ozhrU1MzYmKi+som1js4EGArGYGARoA4iriKOMtfQ6kNtSUd/rZleUaAEWAE+gsB4ijiKuIs5z4dnLfGRhMiI4fzjJszSpxnBBiBgEJAkiSZq4iz/DWM2jDP+YsayzMC/iDAsr2BgCS55zkH5428O4UivDf6ZB2MACPACPQpAsRVxFn+dkJtqK2/7VieEWAEGIH+RoC4ijjLuV8H581sbkVYWKizDOcZAUaAEQg4BIiriLM8GeaqjtpQW1d1XMYIMAKMQCAhQFxFnOVsk4PzRpWSxKtKCQdOjAAjENgISFL3uUqSut82sFFh6xgBRmAoISBJrrmqi/M2lAYdOGNhSxgBRoARYAQYAUaAEegdBNh56x0cWQsjwAgwAowAI9A3CLBWRsAJgcB23m7qobvpZDFnGQFGgBFgBPoAgSoc23ccl/tAM6tkBBiB3kWg585bmx7HdubjzTcpbca2fWdQ29ZNI2uOo3D/uY7GF47sw+4jFzvyfXVSsX8XjtX0lXbWywgMGQSCdiDVR3dhU/5BVNhz26WPse3twOQO8xdF2FRU5vB93TixG+9+pHcoc8wYcLVSj1rHQs4xAoxAACLQY+dN9/eDOKuai9Wrl4uUjcemDoeiu1prDag1NnXANDFtBVanTejI983JTdReb4LJ3DfaWSsjEOgItLcDRvG7u3WrEQbDLVy7Vgf6B8l6/XXodDUiXcO3315HTY0B9C+lbtyoR329Ea6Wrwf6WLtrX2tTE8Laq3D2TKeGiv+5BBOaApI7wiapEVN5CRUd5t7El18ZkKBJ7CjhE0YgmBAYajzXXTer4zs3NXc6W0Aoxk6egEhrbcOFj7EzPx+bNuVjm5hRa6Byml0r+hxn92/Hprfewh/pbtYoKqj80EWYr3yCTda7WbrbLTxqmRKj86KjZ/DBO/l48/V8FB6rwuUju7Ftk9DxdhG+kJULPW0GfLFP6H5b9LtlN45dEWVio9m1kn8ele15U25vuQOl8pMGQWz7hLywUYjyxggMeQRaWsy4ebNBdsiam5tx48Yt3LrVIJw4k+yU0dL0trY2EOG1i11raxuoDb3tu6HBKNrWg47kzBnE74ecP5IbysCFRUej9vwZyxDbzqGiOhoJwy1Zed9wESU7twn+ElxScAAVVk7SHd2NLYIDN729DTuPVIHuE12V1f7zAN4lvnxrM97c/jF0tlm+K8dl3tpEnCanXZZIgZv+ZFsiJkETUwVtpZwT3vk5aG+MgWa8yNs4kmzatB1F5Y2i0GkjPv7P46i2FhP/FvYSF1tV8oER6HMEiLOGKs/12HnTPDwb6m+KhBP2AUrO1MjEJH8jtcex+6ABSYuWY+XKpbi/+WOUfCVqzE1oqvwKtd/NxMpVqzAv4SJOnLoJxM9C5sNjgNsfwsrnn0JyPEB3u01NraKR5bzyUhMeeVbM8C2eCvOJIpwYMRdLV65C+lg9Tn5qcfIq9u/GyZi5Qofo93E1zh8+jhtCQ5OxBhWXYjEvy9r+5Gn5rnRKWjqmRUVj2uNCPm2SkOSNERi6CJBTVlt7U3ba6usbrQ5ZCxSKYX4PetiwYSBnjhw3cuBotq5BOHbC1/Nb16BokDABGsNXOEk3m18JDrt9DOJabJYbcGxPCWqTnpa5J3uWGSUl9AhIGU58DjzwvOCX55di4awxCIOrMkChnoH5gp9WrlqBx2LKcLBU8CJqUPLXMoycS+2XY+5YBcb+61OCH931Z7MnGtMmDMflc1VyQdOZi6gdPwFTRK5i/06cFNy5cqXQ+ewMNBzeh2POsVLiaTHbaGFfC//2FhcLEwZ8YwOGNgLBwHM9dt4QOQnp2Svw7CPxqD2+C29aZ9KaLlzCTXGnav7qNE6e+h80DVOg5opltgvDx+DOsaGgT8yISOGkubjzo0qnFJkoyJIsjotGJNS48+5oWSIyQgG0E81cgvZKKOKUOtGn6PeyGYp6PSph+SSMn4oYW3siJ0sx7xmBIY9Aa2urCInelMOhJpP9bDlkB6w7zlsI/ZbskKPZOQqpkhNHDp1d1RA5VWP6hEac/7IRFecMGJskbjZtIzNeFDNb0YhpFc7dqdP4whgGZbUOOoyH5nYDTuz+GGd1TQgLh/i4KgMiR8WjtfI0SvYX4Z/XyGEiXiReU0AxQjQTW2hoE27Wiu/PbX9CyLrFJI2H4vJFYQNQ8U0txk+im1PiyEiMv8saPo38Du4edxPaC0KntZ0vh55ysS99sAwj4C8CwcRzTvTrL1Q2eeEwTf4eFi5fiuTIczh5pgkmEZax1cpH9Xdw/+RY+bTvdk0wt9hrj8ads2ZgrH0RnzMCAYNA/xhC4dBvv60VIVHXf6AptBAeHuaXMWFhoSK8SgHArs1sBErPztEdcFeJwVuivnsCms4dxNkb4zB9nN04msydUQcqDknEXbMmIw7DcddCMeN2byS0B7dj074yNLksEzNp/7kNBy4ocOfDczFbE0laRErEAzMU+GLPLnywbxc+qp6ElHsVwuN2159oYtviJgjuq4K29gzO68fjzslUQRwZCmU4nXcmc4vra6NTwt8z6se+DXOxPRp83vsIBBvP9dB5a0TFkc9x2cFhggjBKBAzRg1Foxlxd8/APTNFEsfptyvg9dPmVcKDwDiMjm9EQ9hkS59yv+MEgXpoIleZ0dqjfmUlvGMEAgoBcpxokQEtRPBmGDlcoaG+04FChFkpZOpJb3NzixyepVCqJ7lBVRc3FZqWKjRovgu1veGqMRitaIA5TnAd8Q6lpEQo0CpuKEMRd8e9SH92FhK+uYjzLsuqcNWQiHvmTsXYaAUajDZn6ia+KGvFPQvmY86j87F0yWyo6Wty25+9UYlI0rRCW3IR1WMtIVNgnOBIA7TnGi2CbZeg1SkweowlimEpFPtRwu2sN6Ba5sVGVF9rEIX+bNRPd7jYnz5YlhEAgpXniAbQ/QtgOBJG6HDg7c2Wh3Tfehcnh30PKXcJjeNSkD7NgAObtqNQ3DHKS+qvi3JP26RJ0FR/jDffFneg9HycJ1mXdQrckz4X0V+8i03bP8Du7duwZf852GjQZRMIgrsjDGf35mPTzuO8TN41SFw6yBAgx+naNYP8TJsvpjc1+ffcW3h4uEya3nTTIgYKpdbV3fImOkjqY/HI00uwcFask71j8FjaVNT+dTO27ShCYUE+Co8bgJrT2P3ONry7m8qOo+G792G6qzKMgSZej0MFu1D4biHKjcOt+qMxNqEBJ3YIHhVp0zu7UHTkIhqEvMv+4PhRTxiDhss6jBbcaqmx58hCbNt0ELXTUvGYPIsYi5jIKpw8ogdCJmH6v+hQQosa3t6H6sg4S3Of9/b9+MrFPitnQUZARiCYea6HzhvEzFo6slevQNaip/DsT1Zg5cIZHTNd6u89hZUrn8IP6Y5RHJNHCrzVs7E0S9w9ilPa1ClLsDTF+vxFxFTMX7UC2c8txTwxxW9fZ38OfAcLX5gP8hG76KBn8JYLHQtSMO+ZpchOnyTufiFCF6uw0NbAuf2cJXghewmyn57VYTvp5cQIDEYE6HkzClm2tbX7bH5TU7OYMfd90UJ7uzwl47P+xkaT/JqR9kG6msGBfxTRiJTDjolIyVqCFNsU3O2zkPn8CmT+cDYWPrccmcnCwYu/F09nL0XmvNmYv2Q5np2TCLgqQyzueXo5sp+Yh4WLM5G+MNPCi23n8M8rYzCfFhc8L+qfnAXluaM4oRPQu+pPFDts4iY6+4UVmJ9kV9rBkenIFHozvydskquFA7psBZbIeQWmPy74fMlTyMrOFI7pUxZ7hJwDFhYu9YuLhQreGIEeIxDsPBfSYwStChTRNkKzFtgOIQrEiDAAfP6Eij8i6PEnLNKNPe40KxTw76kfd4q4nBEYOAQoREkrP/21gBYbKBThiImJQmxsNG67TYWEhDio1bfJic6pjOpUqhGgMKu/fZCDSK8WGawOnK/jJS5UhDhKu+IjV2Vd2jY1iBBqI2rraOEC0HpTh+rWWCSoOvV3adNZ5fGM+ne2EyGhCLOzvbu67TumfizOrn0pnzMC3UeAeQ6w+5l2H0huyQgEBAJBbgTNblGI0h8Yhg9Xyo4aOWkhISGIjIxARIQCw4aFgxYlSJIESZLkcyqjOmoTHR2F+PhYREUNR2hoiM9dUpiDHDifGwS7YMQMLFwwDtUfF+ODfUU48EWYCNumY3pEsAPD4w9WBJjnLN+876xrkec9I8AIBCAC9NCuP44bLTgYNSoOKjGLRk5Zd4YUHh6G6OhIjBo1UhyjZCcPPnzIgaMXZ/ogyiICgbBRMzDv8XTMp/SDezE2WhTyxggEIQJ9zXOuIA1UnmPnzdW3xWWMwCBCgMKQtbU3QEdvZoeI2bXY2BEYOTJGzJiFehP3uT4qKkKEWWNBTqEvjegFwRRG9UWWZRgBRoARIH5jnuu8DkI6T/mMEWAEBiMCNONGd6TebA8LC5VDnRERSm+i3aoPDQ2VnUIKvfqiwGC4BXrWzhfZ4JLh0TICjIAzAsxzjoiw8+aIB+cYgUGFQFtbG0ymZq82U2iUnlELDe37nzwtevDFgSPbjUaTV9tZgBFgBIIbAeIK5jnHa6DvmdyxP84NIgTY1MBHgP47wqhRcfJCA3fWkuNGYVJJktyJ9Hq5NwcuLCxMzNKpcKPNiK9r9b3ePytkBBiBoYMA81zX75Kdt66YcAkjMCgQIEKjlZv0TjdaBUqv8yBHzd54mmmLi4vxeTGBfduenpMD5/wMXEiIJL+OJCp2ON48UYR/zf8FNvxjT0+74vaMACMQeAj0ikXMc65h7LnzZqqDXq93SnUwmV13GJilJVg7Vg3179A2HQAAEABJREFUiyX+mec09rp6/5qjMg9pot+0zVq5oXZzGtRj05BXSVkTiteoETt2LUo9YtlN26kLToMaAdu/vSJyIweO/rcfvYctLi66YzEC5clhGqiBki30rB31T6HU+IQ4/FV7Cilb/j82lf4Xmswt+O+vTkEb6LNvTr91C+cFF8/VmehbtCUT6oj3bYUX8pAcG4u0d3yYRXXiPZtGPjICrhBgnnOFCnrhPW+HcqBWC8fHISVbHRDXnVJp8RIJ0pJiOg2AZIKuSjig1xzYybtdTmOPHSHGNHYBCiq8N5UlzCZoRb9am9NXr4W+Stvp+ApzxCaLut9103b3CrlmECBACxRMpiYHS43GJlRX16KlpRXx8SoRloyR39fmINTPGUmSECdm/hISYqFtqMbj/7EeL+0vQHX9jQ5L2tGOzcf7kAs6eurBidNv3cJ5wcVzOYfs8StBDnH+mpLOQpN3tpKFnXlPLuQdI9AVAea5rpjYSno+82bVlLFdB53Olo4hZ7y1wuVBL5wllxWDsrBj7Ge2IvXaXixbWQB9j0eiROoWHYyXN+DBsB4rc1Dwq1/9Ck8++aRDGWcGFwL0okpXFtNyepqBq6kx+O24VVVV4ZFHHpFDrKGhofj5z38uHMEWuRuaaaJrRpLEDYpISUlJ+Oyzz+Q6bzuaedv6+UFkCMftrF6eVu7SpKj8BBpbHJ3RLkIBUNDxW5e5Lrh4ziP8E3NwzGjE/ucSPYp1t5I5q7vIDe52/c1zxJ+7du1CTEyMzIN0PHDggE8g9jfP9ZrzplQlIjHRllRQmkux7j411HPzIAcFRX5tkhozX96Bf0+dgVUfAXgvU4QJ1bCEDS3hv1VF5dj4cIQAbio2XhAy14qxdgbl6Y+GkM0vF4W0WeSX5ZdgY6payIt6dZqY9dJjxxJrPjwZG+1nwdzqIn22pEVeirA7w84Bq9+LZRTezNfbhByOHWOfvgAZc0TVrToYxQGw2GgZH0SJ0C1sVadaMRElnraSF4UdImxqubetQ+kvkxEh/nBKkhir8wyf+TTyhG5JEnXO43bqhIhw6tSp7MA54TKYsu5IzTYGIhJJkmxZr0ez2YyXXnoJV65cwfHjx/GXv/wFf/rTn1BQUCC3/eabb2AwGPD555/L9c3NzVi9ejVu3OicQZMF3eymJ45zU2MppvDp386ftmQCeN/xW5e5Lrh4zuPX4hwKNZejIMPKw+I6jBX8qRapkwuFthrB7UmSlbuXobhOlLnZmLPcADPEi/ub586dO4c1a9Zg7dq1qK+vl490fu3aNZ+Q7k+e6zXnTXtkL/b+2ZJKKkyA8kGsezUNpkOrsOq9Oug35wpHaipy1mTg/7ywDhl0gzYrC3mv5SF3jloAYxKzcXrk/d+pyFOvR+H7hcgcf1o4gGnYWJ+JPWd0KNuWjGPZyVh7HOJjkS/IXoDiezdiz+8zoNIXY1mSBuuV67Bnew5mmEuxVjiLwhpAODfr7ktzo0uo69g0WPC4Bvp9BdhTZSk0FRWgoEqD1HlktKXMfm8be96LqVh7QIWMFzOhkQUsNnaERUWZ6bIe+suyRSLneTNdE7JVOsjSFwqQ9W+lSH6jTMxwlmH/mhRo7M15bwP2Eg62cXuZ/WMy9Ix9INc2N7eAls57sjEqKtJTdZe669ev49NPP0VWVhYeeOABpKWl4Uc/+hF27twpk9j999+PQ4cO4Z577pHrH3roIXEd6tDY2NhFl6uCh8ZPw/REj9Px+K/yT101Dagy22+duC5YeY7GvvfPJZabctu3Y3Z8BKRccP+yfVPx1nkjjOffwswqPWLnrbdyvaVR+R82om7NHit3F2DBL0stFW72zFlugBmixQPBc+SwEZxz5sxBZGSkHImgG9Samhoq9pr6k+d6zXkr/cMCLHjSklYV6eRBKudtQMEzShT/IgWpL5ci6fdbkTVGiaTHUjHzNiGiSUHGExlImaIUGes26y0cez8Xi56YgcRDefh1JbDo1fVIFvKx83KQNb4OxUfkuTxLg8WFOPzqImS8tB5rp4ii6euxf0sOMhbnInO6yGtFKFcc4IsukhMp8blVyEApCvfRTJtJOKXFwJwsLBgjKl1spfk5yHkxB+s3l6IuTIylSgsPN5HoyUdXroUhKgmpL+UgRWWnyYbD4g1Ymy7Ka+pgFAdPG5OhJ3QCt87b+45CQ0OgUIT7NYBQESZVKpW4evVqx39qSEhIgFarxa1bt2Rdra2tssOWn5+PPXv2ID09HfHx8XKdL7unvvuwR7Gjl8rQ1t7uUWagK4Oa5+w4fsGTG+HJ1dJWCo6enorUiUooJ4qj4OJycUtrz/VJvz+MrSsyBHevQ04iYKozeP16mbO8QjRkBAaC5yZPnoy77rpLjiqUlpbi4MGDSE5OxsSJE33Gtb94LsRni7wILvqwXSZ9ihmXvWSZdwLELNSaHKgqT+O0OQtvvWArh/vPnRqI37Fcrz17TD7uWKSG5QHhR7FROHNyYZedIImwLoUdBX7pilqEnBVKlG4phNZcgv37gJRn0jrs6lBqPVlEz/tdFk6isR1lr8Zi78uZ2HDWWtlbh4m52LMlA4b8NEwdIUEtwrrlLlehKqFSgT9DGIGWFpdffMeI6R/Hd2R8PBk5ciQee+wxbN68GU888QS+//3v449//KND6+rqasyaNQvZ2dmYOXOmHGal97U5CHnI/DDpfoRK7inH2NKMi9ctN34e1AxoVVDznB3Ht7fvxyIP38TMh1OAswXI+0gL7Ud5KBB8mDEn2U0LFWLFzbmbSi4OUgQGgueioqLw05/+FGVlZbLT9vrrr+NnP/sZwsPDff4W+ovn3DOpz6Z6EtSj4BcbYZqTgiRzAX7tyzJyO3WaKTNETomckk7H0NE5FNU+bv7qSlmUBaUgn73vFGMvUpH1TKJPPSUJ0lKKgIKYsOiQNxh6Zx4uafke6IxGlL2/CBH7liHt1fKOPrpzQnexdJG+//773WnObQYIgZaWFo89O79bzaOwtVKSJGzcuBEffvghRo8ejZdffhmvvPIKyDkLCbHQBN1AXbp0CbR4gZ5v/cEPfgBa5GBV4fUQo4zE1FH/4lHuy28veawPzMrg4zlv30PiEznIUBqwd2UykleeRvK2MhQ+o/TWzGs9c5ZXiIaMwEDw3CeffIIVK1bgH//4B77++ms8+uij8uMjX375pc+49hfPWVjZZ7PcC9o/C0LPRJyuAurey8Kyj5KwfsthFKxWoSQ7CzvqrDqU4vjnQuyo1KPO9qoMUeSwzclElsqEvOxl2HtWL/5oaHG641kLB0nvGV90mepge20RHspB7vhyrFtTAFN6JjKi3HdhqrPadiAPy57Lg0kEXdPmkHwsYsU49UWFKKnUouSXmVh7lsqdknDu7N+LZ6gzOQmIbEUB1v6hBHqTEknkDIsio9mFnCj3ZWMS9AWlwJNpbW1DW1u7R8PCw8M81rurpNBpWloa3njjDaSkpODo0aOYMmWKvPKKQqZ040RtR40ahcWLF6OiogKnT/u3yMDbA70VNZepi4BNwcxz/nwp2vx12Hv3Wuz/TAdd+WFsfS4Jggr9UdFFljmrCyRDtmCgeO5vf/sb7rjjDkybNg0ajUaOPtANLDl1/oDdHzwX4o9BnmTtnwWhZ982fLIXOUuLoVy8ATkiXPzgqwVYpCxG5pIdqIMGWb/MQqJpBzI1amjcPagalYqtpVuRWl+ABd+h0OkdmLkmD6WV8P/jUVcKMp9TAX/ORM4Bm+okrHrxQZhMJmQ8k+GRePYusdqWugp7VFnYc74Qi2Rn70Hk/v5B4OxGPKq5A5mfZ2HDYnR+JmYg616g/LeZoJW1msezMAPl+PXijWLfKUZndXV1KH/tUahFyFSKX4biKbkofHkGVfmdxo8fL08L84yb39ANeIO2tjaPNoSFhUKSJI8y7irp+Q5aXUqza7/5zW9w+PBh/OQnP4FCocBrr70mh1PLy8tBicKrKpUKRHDw4zMlfqxH6WsNNz3WD3RlMPOcP9hr5mUi6fha0CMekiTJ16Qkvw3AHy2dsn3CWZ3q+SzAEBgInqNnfim6QK9AOnXqFOiG9cSJE6DFXOPGjfMLof7guZ47b+mFHc+60Z25LRU+nYFCYzuM21Mtjo/Kkm//cBFUAFTpW0UI0ABdjRGG14SDI0KThe3taBfyorpzm5KF/Tqhp0bcwdUY0a7bg0XjqToVjvIa5J5pR/uZXGioWuwd86LQrS4lUrcZYKwxoIAe9heinVsGFqQrO7P2Zy7GbvhsKzImdsprVh9D+y0xToMRuuIs5G53svEzIwy6Y8idIhRPzMUpo5AtzUWSyKaSbHuhQAZQzcrtxEHoai/fYF2wkOqEAyC368BBKHLaKisrwY6bEyiDJOuN1GwhTn+HQ7/bCxcuyCED+kP5u9/9Dq+//jpoUYIkSaBn4Ch0QK+YofT3v/9dnqGjO1R/+oqPjPEoXmt0Nw3vsVnfV7r4rRNmwcRzhQ7c6MQ7grvKBH9bnnc2ofi1DTC9dFhe4KLT6aA7swEP6ouxsUgLOMjSV6excLcz91OVNVUyZ1mRCI7DQPAcIfvjH/9YXnE/e/Zs+ZERyufm5srhU6r3NfUHz/XcefN1NK7klCok3qZ0VdOlTHlbos+yXRo7FbjTpbxNBWWYEL5Qgrw/LEDymlJofr4Ollk0Ud7dLUqMU+VunEqoEkW/sH6UnmQB2Xa3uqw6+DCYEPDL1jYvIdOQEMkvfTZhSZKwcuVKNDQ04Ntvv5WPlJcki7777rtPnnGjd71RPa1ApdCpJFnqbXq8HeOGj/AoYmi85bF+UFbSb/o2pU+my79vH2W9KXSnq894rsOg0yh+rw4GfR0EuSFR8BvKT4loggrJ09UdUnzCCLhDYKB4jl4PQo+NGI1G0LO9FHn77W9/69eCBRpTf/DcwDpvNMoATNpDG7H+jXJoXtmPU692LzQZgMNik4YAAhERCoweHe820b+i6skww8PDQa8IoaMrPSqVSq6n5+Nc1Xsru3/sJHz9/7a5TfuWvOJNBdf3EgJ9x3MPYn2xiIAULYA6QoIkRUDzCz2y9pZj6zxlL1nPaoYyAgPNc0qlEvRsrzse9IZ9f/Bcp/PmzZogqtes2A/d5TIcfjUVqrAgGjgPlRFgBIIGgb7kOdWcDThlaO94pMZ4/jA2PJ4YNNjyQBmBvkYgpK87YP2MACPACDACQx8BHiEjwAj0HwLsvPUf1twTI8AIMAKMACPACDACPUaAnbceQ8gKAgsBtoYRYAQYAUaAERjaCHRx3mj5+9AeMo+OEWAEhgICPeGqnrQdCtjxGBgBRsANAgFW7I6rHJw3esGn2dwaYKazOYwAI8AIdEWAuIo4q2uN5xJqQ209S3EtI8AIMAIDjwBxFXGWsyUOztuwYeFoampxluE8I8AIMAIBhwBxFXGWv4ZRG2rrb7t+lufuGAFGgBGQfTLiLGcoHJy34cOVaGholJd3OwtynrEJHdoAAAGqSURBVBFgBBiBQEGAQgnEVcRZ/tpEbagt6fC3LcszAowAI9BfCBBHEVcRZzn36eC8kXenUAzDjRv1znKcD1YEeNyMQAAiQBxFXEWc5a951Ibakg5/27I8I8AIMAL9hQBxFHEVcZZznw7OG1WqVCPQ2tqGurpbPANHgHBiBBiBgEGA7kSJm4ijiKu6axi1JR2ki3R2Vw+3YwQYAc8IcK3/CBAnETcRRxFXudLQxXkjoZEjY+iA6upa1Ncb0dJiZkdORoR3jAAj0N8IEJERBxEXESdR/zaOovPuJpsO0km6qQ/qq7v6uB0jwAgwAt1FgLiHOIi4iDiJ9Ng4is6dk0vnjYTI24uNjYbZbIbBcBM63TVcvVrDiTHga4CvgX69Boh7iIOIi4iTiJuIo/xLrqVJF+kk3dQH9cU8xzzP1wBfA/19DRD3EAcRFxEnETe5Zi1LqVvnjaopzkoKEhLiMHp0PCfGgK8BvgYG5BogDiIuIk4iburNRDpJN/XBPMc8z9cAXwMDdQ0QBxEXESd54ziPzpu3xlzvPwLcghFgBBgBRoARYAQYgZ4g8L8AAAD//zZxIHQAAAAGSURBVAMAo4mAFVEGgSoAAAAASUVORK5CYII=" width="623" height="60" alt="PACS’s Sentiment Meter and Message Volume as of 9:15 a.m. ET on Nov. 20, 2025 | Source: Stocktwits"><figcaption>PACS’s Sentiment Meter and Message Volume as of 9:15 a.m. ET on Nov. 20, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/PACS">PACS stock</a> is up by 28% this year and down by about 2% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-urges-china-customers-to-buy-model-y-inventory-as-wait-time-for-custom-orders-stretch-into-2026/cLPAi4CRE9U">Tesla Urges China Customers To Buy Model Y Inventory As Wait Time For Custom Orders Stretch Into 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a PACS Group company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

PACS Group Stock Soars Premarket On Completion Of Audit Committee Probe, Upbeat Full-Year Guidance

The company said the committee's recommendations have been or are being implemented.

Equity

The company said the committee's recommendations have been or are being implemented.


<ul class="summary-bullets"><li>CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>However, the drug didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.&nbsp;</li><li>Anavex confirmed on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation.</li></ul>Shares of Anavex Life Sciences (AVXL) slumped 45% in the premarket session on Friday after a European Medicines Agency (EMA) committee did not recommend a much-awaited approval for the company’s Alzheimer’s drug Blarcamesine.Retail investors were looking forward to the Committee for Medicinal Products for Human Use’s opinion on the drug after it placed Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from Nov. 10 to Nov.13, with the oral explanation held behind closed doors on Nov. 11.<h2 class="st-heading-2">CHMP Avoids Recommendation For Blarcamesine</h2>The CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025">released</a> its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine did not feature on the list. CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.However, the drug also didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/14/3188222/29248/en/Anavex-Life-Sciences-Provides-Regulatory-Update-on-Blarcamesine-for-Early-Alzheimer-s-Disease.html">confirmed</a> on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation. The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/AVXL"> AVXL stock </a>stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.AVXL stock is down 47% this year and by 29% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/avadel-gets-acquisition-proposal-from-lundbeck-weeks-after-inking-agreement-with-alkermes/cLPQetHRE4T">Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

AVXL Shares Slump Pre-Market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.

<ul class="summary-bullets"><li>MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone payments in addition to tiered royalties on licensed products.&nbsp;</li><li>Lilly, meanwhile, will also receive worldwide exclusive access rights to MeiraGTx’s gene therapy technologies for use in ophthalmology.</li></ul>Shares of genetic medicines company MeiraGTx Holdings plc (MGTX) soared as much as 13% on Monday after the company announced a strategic collaboration with Eli Lilly and Company (LLY) in the eye diseases segment.As part of the collaboration, MeiraGTx will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.meiragtx.com/news-releases/news-release-details/meiragtx-enters-strategic-collaboration-eli-lilly-and-company">grant</a> Lilly worldwide exclusive rights to its AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4 (LCA4). Leber congenital amaurosis 4 is a severe, inherited eye disease that causes significant vision loss from birth. Symptoms include involuntary eye movements, sensitivity to light, high hyperopia, and a cone-shaped cornea.Following treatment with AAV-AIPL1, 11 children who were born blind gained vision, the company said, while adding that the treatment also resulted in benefits in vital areas of development, including communication, behavior, learning, mood, psychological benefits, and social integration.<h2 class="st-heading-2">Terms Of The Collaboration</h2>Lilly will also receive worldwide exclusive access rights to MeiraGTx’s gene therapy technologies for use in ophthalmology, in addition to certain rights to its proprietary riboswitch technology for use in gene editing in the eye.In return, MeiraGTx will receive an upfront payment of $75 million and will be eligible to receive over $400 million in total milestone payments in addition to tiered royalties on licensed products.“Ophthalmology is an emerging area of interest for Lilly,” said Andrew Adams, Lilly group vice president of Molecule Discovery.“We are excited to partner with MeiraGTx to bring transformative treatments to patients around the world suffering from eye diseases, starting with AAV-AIPL1, which has shown the unprecedented ability to restore vision in children who were born legally blind,” he added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MGTX">MGTX stock </a>jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:587/59;" src="data:image/png;base64,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" width="587" height="59" alt="MGTX's Sentiment Meter and Message Volume as of 10:18 a.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>MGTX's Sentiment Meter and Message Volume as of 10:18 a.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the stock is undervalued.<stembedurl>https://stocktwits.com/waterlock/message/635582913</stembedurl>Another expressed hopes for FDA approval of AAV-AIPL1.<stembedurl>https://stocktwits.com/ErnieWorthing84/message/635572756</stembedurl>MGTX stock is up by 44% this year and by about 23% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

MGTX Stock Soared 13% Today – What’s The Eli Lilly Angle?

As part of its collaboration with Eli Lilly, MeiraGTx will grant it worldwide exclusive rights to its AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4. 

<ul class="summary-bullets"><li>Intuitive Machines said that the transaction is expected to close in the first quarter of 2026 and noted that, as a stand-alone company, Lanteris is a cash-generating business.</li><li>The company said that the transaction is priced at $800 million, consisting of $450 million in cash and $350 million in Intuitive Machines Class A common stock.</li><li>Intuitive Machines CEO Steve Altemus said that the combined entity's revenue exceeds $850 million.</li></ul>Intuitive Machines (LUNR) said on Tuesday it would buy Lanteris Space Systems, formerly known as Maxar Space Systems, from private equity firm Advent International.The company said that the transaction is priced at $800 million, consisting of $450 million in cash and $350 million in Intuitive Machines Class A common stock.Intuitive Machines said that the transaction is expected to close in the first quarter of 2026 and noted that, as a stand-alone company, Lanteris is a cash-generating business. As a combined company, Intuitive Machines expects to have adequate cash on hand for continued operations.<h2 class="st-heading-2">Executive Take On The Deal</h2>Intuitive Machines CEO Steve Altemus said that the combined entity's revenue exceeds $850 million, with positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA), and $920 million in backlog as of September 30.“This strategic acquisition positions Intuitive Machines as a next generation space prime directly in the flow of multi-billion-dollar space programs,” Altemus said.“Our focus over the last two and half years has been to position Lanteris for sustainable growth by pivoting and investing behind national security priorities including helping enable next generation missile defense for America,” said Managing Partner of Advent, Shonnel Malani.<h2 class="st-heading-2">Intuitive Machines Q3 Results</h2>The company said that the timing associated with its year-end revenue is impacted by uncertainty related to the government shutdown. Intuitive said that based on the current backlog, it expects fourth-quarter revenue to be in line with the third-quarter revenue.<a href="https://stocktwits.com/symbol/LUNR">Shares of Intuitive Machines</a> fell nearly 10% in premarket trading. Retail sentiment on the stock remained unchanged in the ‘bearish’ territory, with message volumes at ‘low’ levels, according to data from Stocktwits.Intuitive Machines’ third-quarter revenue came in at $52.4 million, compared with Wall Street expectations of $66.62 million, according to data compiled by Fiscal AI. Its quarterly net loss was $10.0 million with adjusted EBITDA of $13.2 million.Shares of the company have declined over 36% this year but have jumped nearly 50% in the last 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-slips-in-premarket-session-what-to-expect-from-q3-results/cL284yNR3Cq">AMD Stock Slips In Premarket Session Amid Worsening Tech Sentiment: What To Expect From AI Chipmaker’s Q3 Results</a>

In this photo illustration, the logo of Intuitive Machines, Inc. is displayed on a smartphone screen, with the company's blue branding visible in the background, on May 11, 2025, in Chongqing, China.

Intuitive Machines To Acquire Lanteris Space Systems In $800 Million Deal

The company said that the transaction is priced at $800 million, consisting of $450 million in cash and $350 million in Intuitive Machines Class A common stock.

TG Therapeutics, Inc. (TGTX) on Monday raised the full-year revenue guidance for its multiple sclerosis drug, Briumvi, to reflect strong market demand.The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-reports-third-quarter-2025-financial-results-and">expects</a> full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million. The company also subsequently raised its full-year overall revenue guidance to $600 million, up from its previous forecast of $585 million.<h2 class="st-heading-2">TG’s Blockbuster Drug</h2>Briumvi is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS). Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the myelin sheath, the protective covering of nerve cells in the brain and spinal cord. This damage disrupts nerve signals, leading to a wide range of neurological symptoms, including numbness, vision problems, and difficulties with balance, coordination, and walking.“As we move through the fourth quarter, we remain focused on expanding patient awareness, advancing enrollment into our ongoing clinical trials, and driving growth and long-term value for our shareholders,” CEO Michael S. Weiss said on Monday.The company is currently undertaking two late-stage programs of Briumvi, evaluating subcutaneous and intravenous formulations of the drug.In the third quarter, the company reported total revenue of $161.7 million, of which Briumvi U.S. revenue accounted for about 95%. This also beat an analyst estimate of $152.17 million, according to data from Fiscal AI.Net income for the quarter came at $390.9 million, compared to $3.9 million in the corresponding quarter of 2024. The company ended the quarter with cash, cash equivalents, and investment securities of $178.3 million, which it expects to be sufficient to fund its business, when coupled with Briumvi revenues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/TGTX">Shares of TGTX</a> jumped 4% in the premarket session at the time of writing. On Stocktwits, retail sentiment around TGTX stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed within ‘high’ levels.TGTX stock is up 16% this year and approximately 43% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pfizer-files-second-lawsuit-against-metsera-novo-nordisk/cL2N3Z5R3zi">The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

TG Therapeutics Stock Soars After Company Ups Guidance For Multiple Sclerosis Drug

The company now expects full-year Briumvi U.S. net revenue to be approximately $585 million, up from its previous guidance of $570 million to $575 million.

<ul class="summary-bullets"><li>Limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months, the company said.&nbsp;</li><li>BridgeBio now intends to file a new drug application for the therapy's approval in the first half of 2026. &nbsp;</li></ul>BridgeBio Pharma, Inc. (BBIO) on Monday announced that limb-girdle muscular dystrophy type 2I/R9 patients treated with BBP-418 in a late-stage study demonstrated improvements in motor and pulmonary function at 12 months.Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) is a rare, inherited disorder leading to progressive weakness and wasting of the arm and leg muscles, commonly later accompanied by pulmonary muscle and cardiac muscle involvement. It is caused by mutations in the FKRP gene, impairing glycosylation of alpha-dystroglycan (αDG), a protein associated with stabilizing muscle cells.<h2 class="st-heading-2">Other Trial Observations</h2>BridgeBio<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174417/0/en/BridgeBio-Reports-Positive-Phase-3-Results-for-Small-Molecule-BBP-418-in-LGMD2I-R9-FORTIFY-Study.html"> said</a> that glycosylated αDG increased by 1.8x from baseline at 3 months, whereas the placebo group showed little change. These improvements were sustained at 12 months in BBP-418-treated individuals, it further added.Furthermore, an average reduction of 82% from baseline in serum creatine kinase, a marker of muscle damage, was observed in BBP-418-treated individuals, it added.<h2 class="st-heading-2">Drug Safety</h2>BBP-418 was well-tolerated in the study with no new or unexpected safety findings observed, the company said. Overall, interim analysis data are supportive of a favorable risk-benefit profile for BBP-418, the company said.The company now intends to file a new drug application for approval of the therapy in the first half of 2026. It plans to engage with the U.S. Food and Drug Administration to discuss data from its studies later this year.<a href="https://stocktwits.com/symbol/BBIO">BBIO shares</a> traded 9% higher in the pre-market session at the time of writing. On Stocktwits, retail sentiment around BBIO jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.BBIO stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/neumora-therapeutics-experimental-drug-demonstrates-weight-loss-in-preclinical-studies/cLG030zR3ML">Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial

BridgeBio (BBIO) now intends to file a new drug application for the therapy's approval in the first half of 2026.

<ul class="summary-bullets"><li>Retail sentiment on Krispy Kreme stock jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago on Stocktwits.</li><li>Morgan Stanley kept its ‘Underweight’ rating on the stock with a $2.5 price.</li><li>Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends, Morgan Stanley said.</li></ul>Krispy Kreme (DNUT) stock traded above the 200-day moving average (DMA) for the first time since November 2024 and experienced an over 8,200% increase in retail user message count over 24 hours on Stocktwits, as of Wednesday morning, following a Morgan Stanley note that it was the top-performing restaurant stock in the third quarter.The stock touched a high of $5.11 on Wednesday versus the 200-DMA level of $4.66 earlier in the day. However, it had pared some of the gains as of the time of writing.Retail sentiment on Krispy Kreme jumped to ‘extremely bullish’ territory from ‘bearish’ compared to a day ago, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Analyst Take On DNUT</h2>Morgan Stanley kept its ‘Underweight’ rating and a $2.5 price target on Krispy Kreme, according to MT Newswires. The firm noted that Krispy Kreme was the top-performing stock, despite a broader slowdown in overall sector trends.“Restaurants as a whole have performed poorly as industry data show a slowdown beginning in September,” Morgan Stanley said.<a href="https://stocktwits.com/symbol/DNUT">Shares of Krispy Kreme</a> have lost over 60% of their value in the last 12 months.<h2 class="st-heading-2">Recent Developments At Krispy Kreme</h2>Last week, Krispy Kreme announced the opening of its first store in Madrid, Spain, on October 2, 2025, through a minority interest joint venture with Glaseados Originales S.L. The company said that additional shop openings in Brazil and Uzbekistan are planned before the end of 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/beyond-meat-stock-skyrockets-60-today-meme-stock-frenzy-intensifies-after-etf-inclusion-amid-surging-retail-buzz/cLG5aNdR3qg">Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz</a>

The Krispy Kreme corporate logo is displayed on a sign at their store on January 31, 2025 in San Diego, California. (Photo by Kevin Carter/Getty Images)

DNUT Stock Trades Above 200-DMA For The First Time Since November 2024

Morgan Stanley kept its ‘Underweight’ rating and $2.5 price target on Krispy Kreme.

<ul class="summary-bullets"><li>Beyond Meat stock experienced a 200% increase in retail user messages on Stocktwits.</li><li>Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.</li><li>Retail sentiment on Beyond Meat remained unchanged in the ‘extremely high’ territory.</li></ul>Beyond Meat (BYND) saw a nearly 200% surge in retail user messages on Stocktwits over the last 24 hours, with its shares jumping over 60% in early trading on Wednesday, mirroring a meme-stock rally following its addition to the Roundhill Meme Stock ETF (MEME).Retail sentiment on <a href="https://stocktwits.com/symbol/BYND">Beyond Meat</a> remained unchanged in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels, according to data from Stocktwits.<h2 class="st-heading-2">Retail Users’ Take On The Stock Surge</h2>A bullish user on Stocktwits noted that the stock could surpass the $10 mark.<stembedurl>https://stocktwits.com/MarketWhispererr/message/633216899</stembedurl>Another user said that Beyond Meat was mirroring GameStop.<stembedurl>https://stocktwits.com/InvestingCat/message/633216438</stembedurl><h2 class="st-heading-2">Stock Milestones</h2>Beyond Meat’s stock has surged over 1,300% from Thursday’s closing price of $0.52. The stock has been gaining every day since then and hit a high of $7.69 in Wednesday’s trading.Last week, the company announced the early settlement of its previously announced exchange offer for convertible senior notes due 2027.Analysts have noted that the firm’s growth has been impacted by increased competition, adverse shifts in consumer perceptions of the health attributes of Beyond Meat products, and termination fees from co-manufacturers.Shares of Beyond Meat have gained over 43% this year but have declined nearly 13% in the last months.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/applied-digital-stock-soars-7-premarket-on-5-b-ai-factory-lease/cLG5JkyR3q7">Applied Digital Stock Soars 7% Pre-Market On $5B AI Factory Lease With US Hyperscaler</a>

A group of bondholders of Beyond Meat are reportedly working with the company’s law firm for a possible restructuring.

Beyond Meat Stock Skyrockets 60% Today: Meme Stock Frenzy Intensifies After ETF Inclusion Amid Surging Retail Buzz

Roundhill Investments said that Beyond Meat has been added to the Roundhill Meme Stock ETF.

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Candel Therapeutics (CADL) on Tuesday said that it has entered into a five-year, $130 million term loan facility with Trinity Capital (TRIN).The loan facility <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/14/3166168/0/en/Candel-Therapeutics-Enters-into-130-Million-Term-Loan-Facility-with-Trinity-Capital-Inc.html">comprises</a> four tranches. While the first tranche of $50 million will be drawn upon closing of the agreement, the second and third tranche totaling $50 million will be available to draw on the achievement of certain milestones, and the fourth tranche of $30 million will be available at the lender’s discretion, the company said. The loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.Proceeds from the loan will be used to refinance certain loan and security agreements, as working capital, and to fund general corporate purposes. The company also said it intends to use the proceeds towards the initiation of a pivotal phase 3 clinical trial of its lead candidate CAN-2409 in non-small cell lung cancer in the second quarter of 2026.Candel Therapeutics shares traded 7% lower on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CADL">CADL stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.Candel CFO Charles Schoch said that the strategic financing, in addition to the company’s cash and cash equivalents of $87.2 million as of September 30, strengthens the company’s balance sheet and is also expected to support the company through CAN-2409’s potential launch in early localized prostate cancer and into commercialization.The company plans to submit an application to the U.S. Food and Drug Administration (FDA) for the approval of CAN-2409 for prostate cancer in the fourth quarter of 2026.CADL stock is down by 31% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-major-shareholder-calls-for-sale-of-company-to-larger-pharma-entity/ch6moRsR3mh">Novavax Major Shareholder Calls For Sale Of Company To Larger Pharma Entity</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Candel Therapeutics Enters $130M Term Loan Facility To Advance Lead Product Candidate In Treatment Of Lung Cancer 

The company said that the loan facility has a five-year term with an interest-only period of 36 months, extendable for an additional 12 months upon achievement of a certain commercial milestone.

VTWG
Vanguard Russell 2000 Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VTWG News

VTWGVanguard Russell 2000 Growth ETF